The Hidden Costs of Prior Authorization: When Saying Yes Can Save More Than Saying No

Why a $27,000 “Savings” on Specialty Drugs Didn’t Show Up On the Bottom Line

Last year, I watched a 900-employee distributor wrestle with prior authorizations for inflammatory drugs like Humira and Enbrel. Their PBM showed $27,000 in annual “savings” thanks to denied claims for non-preferred brand biologics. The HR team thought they’d scored an easy win. But complaints from employees, a spike in appeals, and unplanned overtime for the benefits coordinator told a different story. By year-end, sick time and lost productivity in just two departments cost about $19,000, not counting pharmacy technician overtime at the PBM. The actual net savings? Closer to $2,000, and that doesn’t include employee dissatisfaction or turnover risk.

Most prior authorization (PA) policies start with good intentions: keep expensive or inappropriate drugs in check. But in practice, PA brings a host of “hidden” costs, especially for mid-market employers who don’t have staff dedicated to wrangling paperwork. Before defaulting to more PA, it’s worth asking whether the administrative hassle and clinical delays actually undermine what looks like pharmacy savings on paper.

Administrative Burden: What Your PBM Isn’t Telling You

PBMs tout PA as a clinical safeguard, but they rarely show employers the full operational cost. Each prior authorization can take anywhere from 30 to 90 minutes of staff time, split between provider clinics, PBM review teams, and your own HR or benefits staff. Multiply that by hundreds of requests a year, and the time drain becomes obvious.

A 400-employee engineering firm I worked with saw about 120 PA requests annually, mostly for brand-name ADHD meds and respiratory inhalers. Their HR manager estimated she spent 8-10 hours a month forwarding PA paperwork, tracking down doctors, and answering employee questions. At her $32/hour salary, that’s over $3,800 a year. Add in provider office labor and lost clinical time, and the system-wide burden easily eclipsed any marginal plan savings from blocking a few brand claims.

PBMs like CVS Caremark and Express Scripts aren’t billing you directly for their PA review teams, but those costs show up in network and admin fees. For self-funded employers, every hour your clinic or HR staff spends chasing down a PA is time not spent on onboarding, compliance, or other benefits initiatives that actually move the needle. More friction also leads to more calls to your benefits team, putting HR staff in the hot seat for clinical denials they never chose.

While PA has its place, especially for high-cost therapies and costly new-to-market drugs, administrative overhead needs to be part of the savings math. Don’t be afraid to ask your PBM for actual data on PA frequency, turnaround times, and downstream appeals costs. Some plans can recoup hours (and goodwill) by removing PA on stable therapies for chronic conditions where clinical abuse risk is low.

Treatment Delays: The Cost of Waiting, For Employers and Employees

Every PA denial or delay is a potential medical risk. A standard PA can take two days, but appeals, missing paperwork, or coverage questions can stretch out for weeks. For time-sensitive conditions like asthma, ADHD, or cancer, even a three-day delay can mean missed work, ER visits, or a health setback that lingers for months.

Take a 200-person law firm I advised: one partner’s biologic for Crohn’s disease was stalled for nine days pending PA and step therapy documentation. She spent five days unable to work, used short-term disability, and ultimately filled her prescription with a cash discount card while the PA was processed. The pharmacy plan saved $4,800 by not approving the initial script, but the firm paid $9,200 in legal temp coverage. The benefits director told me later, “We saved ourselves into a loss.”

Delays don’t always show up as hard costs on a pharmacy report, but they eat into productivity, morale, and trust in benefits. For plans with a lot of highly paid or specialized employees, the cost of absenteeism often dwarfs the PA “savings.” Employees may also turn to cash-pay options like Mark Cuban Cost Plus or GoodRx if plan coverage is slow, eroding your network discount leverage and disrupting data tracking for stop-loss and actuarial reviews.

Meanwhile, frequent PA roadblocks can increase employee turnover risk, especially for those managing chronic conditions. If your team’s getting complaints, or if you see repeated appeals for certain drug classes, look at whether PA is saving enough to justify the downstream disruption.

When Removing PA Actually Saves Money (and Sanity)

There’s a myth that more prior authorization always equals more pharmacy savings. In reality, selective removal of PA on low-abuse drugs or well-controlled chronic conditions can cut hidden costs so much that the plan saves net dollars, even if a few more brand claims sneak through.

Let’s look at a real scenario: a 700-employee manufacturing firm spent $1.2M annually on pharmacy, with a $138 PMPM and 90.4% GDR. Their PBM required PA for every new prescription of asthma inhalers, brand or generic. After a year, HR logged more than 140 employee complaints, 60 missed workdays, and a spike in $0 copay manufacturer coupons via discount pharmacy programs. The actual plan savings from the extra PA hurdles? $14,000. But after accounting for $8,800 in HR overtime and $12,500 in temp coverage for missed shifts, the net was negative. Dropping PA for generics (and just keeping it for high-cost brands) reduced complaints by 75% and, after one year, saved $11,200 in net costs.

You don’t have to take an all-or-nothing approach. Smart plans work with a pharmacy benefits consultant to identify where PA genuinely changes prescribing (think new GLP-1 weight loss drugs like Wegovy at $1,200/month) versus where it’s just red tape. Removing PA on low-cost generics, or for employees who have been stable on a drug for 12+ months, rarely leads to major overspending. It often unclogs your HR inbox and keeps employees on therapy, boosting both health and productivity.

For specialty drugs or high-abuse classes, PA remains a useful guardrail. But blanket PA on every new claim can backfire, especially on widely accepted, clinically appropriate drugs. If you’re seeing lots of denials overturned on appeal, or if your appeals process is creating more work than savings, it’s time to review your PA criteria. PBM reporting can help, but sometimes you need your own claims analysis or a tool like RxPBM.ai to cut through the dashboard noise.

How to Right-Size Your Prior Authorization Program

Every employer group is different. A 5,000-life school district with heavy specialty spend needs tighter clinical controls than a 250-employee IT startup with mostly generic claims. Start by mapping your current PA volume and identifying drug classes where denials don’t translate to real savings. If your PA process mostly blocks low-cost generics or stable maintenance drugs, you’re probably burning more money than you’re saving.

Ask your PBM or consultant for a breakdown: what percent of PAs are denied, how many are later approved after an appeal, and where does employee disruption hit hardest? If you see a high volume of appeals, especially those ultimately granted, you’re likely costing the plan, and your people, more than necessary.

It’s also worth reviewing how PA criteria are set. Many PBMs default to manufacturer recommendations, which can be clinically appropriate but administratively heavy. A custom PA protocol, designed in partnership with a pharmacy expert and aligned to your unique utilization, may cut busywork and focus controls where they matter. Cross-reference your claims data with a tool like RxInfo.ai to spot categories where PA adds more hassle than value.

Finally, don’t underestimate the impact on morale and benefits trust. Employees who feel their plan blocks needed care are less likely to engage in wellness or cost-saving programs. If you’re getting a steady stream of complaints about “paperwork just to get my meds,” you may be protecting the pharmacy budget at the expense of everything else.

Prior authorization is a useful tool, but it’s a scalpel, not a sledgehammer. Review your PA policies each renewal, ask for real-world cost data, and don’t hesitate to ditch the red tape when the numbers say it’s the right move.